AK 001

Drug Profile

AK 001

Alternative Names: AK001

Latest Information Update: 20 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johns Hopkins University School of Medicine
  • Developer Allakos
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antibodies; Skin disorder therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Nasal polyps
  • Phase I Hypersensitivity

Most Recent Events

  • 01 Jan 2018 Allakos completes a phase II trial in Nasal polyps (Combination therapy) in United Kingdom, Spain, Netherlands, Germany, Belgium, USA (IV) (NCT02734849)
  • 29 Nov 2016 Allakos in-licenses Siglec-8 receptor intellectual property from The Johns Hopkins University School of Medicine
  • 08 Sep 2016 Phase-II clinical trials in Nasal polyps (Combination therapy) in USA (IV) (NCT02734849)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top